Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)
Clinical trial NCT05650164 · COMPLETED
Trial details
- NCT number
- NCT05650164
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2023-01-25
- Primary completion
- 2023-10-13
- Enrollment
- 171
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.